Planes, Trains, and VTEs
Simple recommendations can help mitigate risk for travel-related blood clots
In November 2011, hematologist Suely Rezende, MD, PhD, deplaned from a flight from Lisbon to São Paulo, where she was scheduled to speak at a...
Online Exclusives
New Policy Takes Aim at “Secret” Hospital and Insurer Negotiations
In a proposed rule, the U.S. Department of Health and Human Services (HHS) announced it is considering requiring U.S. hospitals and insurers to publicize...
Opioid Prescriptions Down, But Pain May Be Up
Since the Centers for Disease Control and Prevention (CDC) issued strict guidelines to curb inappropriate patterns of opioid prescription, the prescribing rate has declined....
News
From the Blood Journals
Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in...
For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML
Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...
Multimedia
Pulling Back the Curtain: Dan Pollyea, MD, MS
In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...
Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism
Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...
Ravulizumab: A New Treatment Option for PNH?
Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda
Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.
On Location
A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?
A study of patients with bone marrow failure (BMF) and short telomeres found that a...
Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial
For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT),...
Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL
For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of...
Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL
For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response...
Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma
Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome...
An ASH Annual Meeting Post-Vivum
“So, what did you learn from ASH?” asked my advisor a couple of weeks after...
Latest Headlines
ASH Directions
ASH Recommends Changes to Continuing Board Certification, and more
ASH Recommends Changes to Continuing Board Certification
In December 2018, a commission appointed by the American Board of Medical Specialties (ABMS) and other entities released...
An Advocacy Win for Sickle Cell Disease
An Advocacy Win for Sickle Cell Disease
As part of a multifaceted initiative to address the burden of sickle cell disease (SCD) in the U.S....
Boston Children’s Hospital Receives $1.5 million for SCD Research, Fred Hutch Names New Endowed...
Weill Cornell Researchers Awarded $9 Million for Lymphoma Research
The National Cancer Institute (NCI) awarded a five-year, $9-million Program Project Grant (P01) to Weill Cornell...
Remembering Evan Sadler and Charles Dobbs, and more
Remembering Evan Sadler (1951 – 2018)
Evan Sadler III, MD, PhD, the Lang Professor of Medicine and Chief of Hematology at Washington University in St....
Remembering Peter R. Galbraith and Sir David Weatherall, FDA names Amy Abernethy new Deputy...
Remembering Peter R. Galbraith (1931 – 2018)
Peter R. Galbraith, MD, FRCPC, an emeritus professor at Queen’s University in Kingston, Ontario, passed away on October...
Planes, Trains, and VTEs
Simple recommendations can help mitigate risk for travel-related blood clots
In November 2011, hematologist Suely Rezende, MD, PhD, deplaned from a flight from Lisbon to...
Is the Era of Traditional Chemotherapy for Hodgkin Lymphoma Over?
Treatment of Hodgkin lymphoma (HL) has been one of the greatest success stories in oncology, with the invention of radiation therapy and combination chemotherapy...
Finding Homes for Orphans
The unique challenges of researching, managing, and developing orphan drugs for rare diseases
Rare diseases are having a moment, and not just in the field...
